Deal Closed | HCP Healthcare Asia Pte. Ltd | Acquisition of 11.5% Share Capital of Eucare Pharmaceuticals Private Limited

The details of the deal are as under:

Announcement Date: 12-Jan-2021 

Completion Date: 12-Jan-2021 

Name of Client: HCP Healthcare Asia Pvt Ltd 

HCP is a group company of Vivasante URGO life sciences group and is primarily engaged in promoting and marketing URGO’s healthcare products in Asia Pacific countries. Vivasante URGO group is based out of France and is a leading global player in (a) advanced wound care management; and (b) innovative self-care consumer brands such as Urgo Consumer Healthcare, Juva Santé and Superdiet etc. 

Deal Description: Acquisition of an additional 11.5% of the share capital of Eucare Pharmaceuticals Private Limited (Eucare) by HCP Healthcare Asia Private Limited (HCP) by way of a secondary transaction under the government approval route. 

Total Consideration: Confidential 

Team Members: The core transaction team comprised of Rajat Mukherjee (Partner), Sarthak Sarin (Partner) and Akshay Sharma (Senior Associate). 

Atul Pandey (Partner), Hirak Mukhopadhyay (Senior Associate) and Varun Yadav (Associate) assisted on the regulatory aspects of the transaction including obtaining the approval from the Department of Pharmaceuticals.  

Role of Firm: We assisted and advised HCP Healthcare Asia Private Limited in acquiring an additional 11.5% of the share capital of Eucare Pharmaceuticals Private Limited (Eucare) under the government approval route.  

Other legal advisors: Legal counsel to the seller: Universal Legal.